Short answer
Lexeo Therapeutics, Inc. (LXEO) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$20M
- +31.2% YoY · +22.3% QoQ
- EPS (diluted)
- −$0.19
- +78.9% YoY · +64.8% QoQ
Source: XBRL data from the Lexeo Therapeutics, Inc. (LXEO) Q3 2025 10-Q on SEC EDGAR. USD.
Lexeo Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- October 2025 Financing Transactions added to funding history, increasing dependence on future capital raises
- Net loss $79.0 million for nine months ended September 30, 2025, with accumulated deficit $359.2 million
- FDA and EMA gene-therapy requirements remain changeable, complicating approval timing and development costs
- Novel AAVrh10 therapies face uncertain safety, efficacy, and scalable manufacturing outcomes
- Cash, equivalents, and U.S. Treasury investments $122.8 million, expected to fund operations into 2028
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Lexeo Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.